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Using Historical Lesion Volume Data in the Design of a New
Phase II Clinical Trial in Acute Stroke
John Whitehead, PhD; Kim Bolland, PhD; Elsa Valde`s-Ma´rquez, PhD; Anela Lihic, MD;
Myzoon Ali, MRes; Kennedy Lees, MD, FRCP; for the VISTA Collaborators
Background and Purpose—Clinical research into the treatment of acute stroke is complicated, is costly, and has often been
unsuccessful. Developments in imaging technology based on computed tomography and magnetic resonance imaging
scans offer opportunities for screening experimental therapies during phase II testing so as to deliver only the most
promising interventions to phase III. We discuss the design and the appropriate sample size for phase II studies in stroke
based on lesion volume.
Methods—Determination of the relation between analyses of lesion volumes and of neurologic outcomes is illustrated
using data from placebo trial patients from the Virtual International Stroke Trials Archive. The size of an effect on lesion
volume that would lead to a clinically relevant treatment effect in terms of a measure, such as modified Rankin score
(mRS), is found. The sample size to detect that magnitude of effect on lesion volume is then calculated. Simulation is
used to evaluate different criteria for proceeding from phase II to phase III.
Results—The odds ratios for mRS correspond roughly to the square root of odds ratios for lesion volume, implying that
for equivalent power specifications, sample sizes based on lesion volumes should be about one fourth of those based
on mRS. Relaxation of power requirements, appropriate for phase II, lead to further sample size reductions. For
example, a phase III trial comparing a novel treatment with placebo with a total sample size of 1518 patients might be
motivated from a phase II trial of 126 patients comparing the same 2 treatment arms.
Discussion—Definitive phase III trials in stroke should aim to demonstrate significant effects of treatment on clinical
outcomes. However, more direct outcomes such as lesion volume can be useful in phase II for determining whether such
phase III trials should be undertaken in the first place. (Stroke. 2009;40:1347-1352.)
Key Words: magnetic resonance imaging scan  phase II trial  sample size  stroke database
Clinical research into new interventions for patients withacute stroke is complicated, costly, and too often unsuc-
cessful. Whereas the NINDS study of tPA1 found significant
evidence of a worthwhile treatment effect and the first
SAINT trial2 demonstrated a modestly beneficial effect, other
substantial phase III trials, including the GAIN study3 and the
second SAINT trial,4 have failed to find an advantage of
treatment. Such negative experiences have underlined the
need for careful clinical research before the launch of
definitive studies and in particular for high-quality phase II
studies. At the same time, the development of reliable
imaging techniques based on computed tomography (CT) and
magnetic resonance imaging (MRI) scans has allowed re-
searchers to form a clearer picture of the direct effects of
treatment on lesion volume.5–7 Although demonstration of a
treatment effect on lesion volume may not by itself be
clinically convincing nor sufficient for licensing purposes, it
can provide compelling motivation for the phase III study of
an agent intended to act through limiting infarction size. It is
thus appropriate to conduct phase II studies of such treat-
ments primarily to establish a convincing effect in terms of
lesion volume.
The purpose of this article is to present design methodol-
ogy, in particular the computation of sample size. Investiga-
tors have experience with deciding the size of neurologic
effect that a phase III trial should be powered to detect. We
consider the magnitude of effect on lesion volume that is
consistent with the specified effect on functional outcome.
Usually the effect on lesion volume will be greater and easier
to demonstrate with small to moderate samples. The approach
to design is illustrated with data from the Virtual International
Stroke Trials Archive (VISTA).8 These data were not col-
lected with our purpose in mind, they are not ideal, and we do
not present our findings on the relation between lesion
volume and neurologic outcomes as definitive conclusions on
the matter. The comparator to our approach is the current
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strategy of either conducting no phase II study at all, or else
designing such a study without formal regard to the magni-
tude of effect that would be consistent with a positive finding
at phase III. Against this standard of comparison, the use of
some data, even if imperfect, is far better than the use of none.
Were the methodology of this article to be taken up, more
satisfactory data might be collected specifically for this purpose.
For simplicity we consider only the comparison of a single
experimental treatment and placebo, with patients being
randomized in equal numbers between the 2 study arms. The
phase II study is conducted to decide whether or not to take
the experimental treatment forward to a full phase III trial. In
phase II, the primary response will be lesion volume as
determined by CT or MRI scan at 90 days after randomiza-
tion to treatment. A secondary response of the phase II study,
which will become the primary response of any subsequent
phase III trial, is the functional outcome assessed by the
modified Rankin Score (mRS) at 90 days after randomization,
or earlier if it is the last observation carried forward.
Methods
Establishing the Relation Between Lesion Volume
and mRS
Cross-tabulation of 90-day mRSs and lesion volumes as recorded at
90 days was made for 301 patients (Table 1). This was achieved with
data from VISTA, which contains records from  27 500 patients
treated within major clinical trials. The identification of some of the
studies in the VISTA database when used for particular analyses is
constrained by agreements with the contributing parties, and they
were used in this investigation without specification of the individual
sources. Records of 1300 placebo-treated patients who had acute
ischemic stroke and had recorded mRSs at 90 days were extracted.
Lesion volumes at 1, 7, or 90 days, all measured by assessors blinded
to treatment group with CT scanning stroke, were available for 309
of these patients. The latest of these scores was used in the analysis
(last observation carried forward). Eight more patients were removed
from the dataset owing to other missing or inconsistent data. The
method introduced here requires both lesion volume and mRSs to be
classified into a small number of discrete groups. The method is
illustrated with lesion volumes classified into the 7 groups: 5, 5
and 25, 25 and 50, 50 and 75, 75 and 100, 100 and
125, and 125 cm3 and mRSs classified into the 7 groups: 0, 1, 2,
3, 4, 5, and 6 (death), although other classifications could be used.
Quantifying Treatment Effect
The data presented in Table 1 represent a sample of placebo patients.
To build a picture of patients treated with a drug having the desired
effect, a statistical model known as the proportional odds model9 is
used. The model concerns ratios such as that of the probability that
the lesion volume is 50 to the probability that it is 50: known as
the odds that the lesion volume is 50. Suppose that these odds are
L times greater for a patient on active treatment than for a patient
on placebo (the symbol L represents this multiple and is known as
the odds ratio). The larger the value of L, the greater the benefit of
active treatment, with L1 when the 2 treatment groups have
identical lesion volume distributions. It is assumed that the same
multiple, L, applies if we dichotomize the scale at 5, 25, 75, 100, or
125 instead of 50. For any given value of L, this model can be
used to transform the observed proportions of placebo patients in
each of the lesion categories to corresponding proportions of
active treatment patients.
If the treatment acts solely through limiting lesion volume, the
effect passed on to mRSs can be found from the cross-tabulation of
lesion volumes and mRSs. This process is demonstrated numerically
in the Results section, and it leads to the construction of the
distribution of mRSs for patients on active treatment that would
follow from the assumed effect on lesion volume. Comparison of this
distribution with that observed for placebo patients leads to an
approximate value for the odds ratio for mRSs, denoted by M.
Sample Size Calculations
The clinically relevant value of the odds ratio M for mRSs was
deduced by consideration of recent phase III stroke trials and by use
of a “number needed to treat” criterion. This is the value that, if
present, would be undesirable to miss. The corresponding value of
the odds ratio L for lesion volumes was found from the cross-
tabulation of lesion volumes and mRSs. A standard sample size
calculation10 was then used to find out how many patients to include
in the phase II trial.
Simulations
Four criteria for advancing the active treatment through to phase III
testing were explored using simulation. Criterion (a) is that lesion
volumes in the active treatment group should be significantly lower
than those on placebo at level 0.4 (2-sided) according to a
Mann–Whitney test. Criterion (b) is that mRSs in the active
treatment group should be significantly lower than those on placebo
at level 0.4 (2-sided) according to a Mann-Whitney test. Criterion
(c) is that criterion (a) is satisfied and there is “a trend” (no matter
how small) toward reduction of mRSs. Criterion (d) is the same as
criterion (c), but with  set at 0.48. The choice of these values of 
is justified in the Discussion. For simulations under the null
hypothesis, the lesion volume for each patient was generated
according to the distribution found from the VISTA data, regardless
of whether the patient was on active treatment or placebo. Under the
alternative hypothesis, lesion volume data for placebo patients were
generated as described, whereas lesion volumes for active treatment
patients followed the distribution derived assuming the given odds
ratio L. Under both hypotheses, the mRS outcome of a patient was
generated from the lesion volume already determined, from the
Table 1. Cross-Tabulation of Lesion Volume (cm3) and mRS, Both Assessed at 90 Days in 301 Placebo Patients
Lesion Volume
mRS, n (Row %)
Total (Col %)0 1 2 3 4 5 6 (Death)
5 23 (28.05) 20 (24.39) 13 (15.85) 9 (10.98) 11 (13.41) 2 (2.44) 4 (4.88) 82 (27.24)
5–25 8 (11.11) 21 (29.17) 9 (12.50) 11 (15.28) 7 (9.72) 6 (8.33) 10 (13.89) 72 (23.92)
25–50 2 (5.88) 5 (14.71) 9 (26.47) 8 (23.53) 5 (14.71) 0 (0) 5 (14.71) 34 (11.30)
50–75 0 (0) 1 (5.88) 2 (11.77) 4 (23.53) 7 (41.18) 0 (0) 3 (17.65) 17 (5.65)
75–100 0 (0) 2 (10.00) 2 (10.00) 6 (30.00) 6 (30.00) 2 (10.00) 2 (10.00) 20 (6.65)
100–125 0 (0) 0 (0) 1 (5.88) 3 (17.65) 7 (41.18) 2 (11.77) 4 (23.53) 17 (5.65)
125 0 (0) 0 (0) 0 (0) 3 (5.09) 14 (23.73) 9 (15.25) 33 (55.93) 59 (19.60)
Total 33 (10.96) 49 (16.28) 36 (11.96) 44 (14.62) 57 (18.94) 21 (6.98) 61 (20.27) 301
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cross-tabulation of lesion volumes and mRSs. For each scenario
100 000 simulations were run.
Results
Establishing the Relation Between Lesion Volume
and mRS
Of the 301 patients extracted from the VISTA database, 178
were female and 123 male. The age distribution was as
follows: 34 younger than 50; 47 in their 50s; 93 in their 60s;
117 between 70 and 84; and 10 age85. None of the patients
received rt-PA. The cross-tabulation of lesion volume and
mRS at 90 days for these 301 patients is presented in Table 1,
and a graphic representation of the relation is given in the
Figure. The Spearman correlation coefficient for this table is
0.586, which is significant with P0.0001 (2-sided). (This is
consistent with values of 0.5411 and 0.6112 reported elsewhere
for correlations between lesion volumes and NIHSS scores.)
The first row of Table 2 presents the percentages of placebo
patients in each of the 7 lesion volume categories and is taken
from the final column of Table 1. The second row shows the
percentages for active treatment consistent with a propor-
tional odds model with odds ratio L1.7070 (a value that
will be justified in due course).
Table 1 is used to find what distribution of mRSs would be
anticipated for an agent having the effect on lesion volume
shown in Table 2. The percentage of patients on active drug
expected to lie in mRS category 0 is found by reading down
column 1 of Table 1 and is taken to be 28.05% of those with a
lesion volume 5, 11.11% of those with a lesion volume
between 5 and 25, 5.88% of those with a lesion volume between
25 and 50, and so on, to give 0.272428.050.239211.11
0.11305.880.056500.066500.056500.19600
10.96% expected to lie in mRS category 0. The proportions
with the different lesion volumes are taken from the second
row of Table 2, so that 0.3900280.2514110.09826
0.045100.050100.040300.1250014.31% of
patients on active drug are expected to have an mRS of 0.
Proceeding in this way, the distributions for placebo and
active drug shown in Table 3 are found. The effect illustrated
in Table 3 is not an exact proportional odds model. It can be
approximated by such a model in which the odds ratio for
mRS is M1.3389.
Quantifying Treatment Effect
One way of expressing the magnitude of the effect is via the
“number needed to treat” as expressed by Lees et al.2 From
Table 3 it can be seen that the expected mRS for placebo is
00.109610.162820.1196 …60.20273.1628,
whereas for the active drug a similar calculation gives 2.8295.
The difference between the 2 expected mRS values is 0.3333,
so that the benefit of active drug amounts to an average
improvement of 0.3333 points on the mRS scale per patient,
or 1 point per 3 patients. Hence, the odds ratio L1.7070 for
lesion volumes, which forms the basis of Table 3, corre-
sponds to the “number needed to treat” equal to 3. Table 4
shows the results of several similar sets of calculation. In each
case, computation starts with the odds ratio for the effect of
treatment on lesion volume given in the fourth column and
uses the transition probabilities shown in Table 1, together
with the proportional odds models, to find the corresponding
odds ratio for the effect of treatment on mRS and the
associated number needed to treat. From a large number of
0
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40
Freq
0 1 2 3 4 5 6
<=5
5-25
25-50
50-75
75-100
>125
mRS score
lesion volume
cm^3
MRS by Lesion volume at 90 days (LOCF)
Figure. Diagrammatic representation of the relation between
lesion volume (cm3) and mRS, both assessed at 90 days in 301
placebo patients.
Table 2. Tabulations of Observed Lesion Volumes (cm3) at 90
Days for Placebo and Corresponding Constructed Values for
Active Treatment Under the Proportional Odds Model With Odds
Ratio1.7070
Treatment
Lesion Volume, cm3
5 5–25 25–50 50–75 75–100 100–125 125
placebo 27.24 23.92 11.30 5.65 6.65 5.65 19.60
active 39.00 25.14 9.82 4.51 5.01 4.03 12.50
Table entries represent the percentage of patients in each category, by
treatment.
Table 3. Tabulations of Observed mRSs at 90 Days for
Placebo and Corresponding Constructed Values for Active
Treatment Corresponding to an Effect on Lesion Volume With
Odds Ratio L1.7070
Treatment
mRS at 90 Days
0 1 2 3 4 5 6 (Death)
Placebo 10.96 16.28 11.96 14.62 18.94 6.98 20.27
Active 14.31 19.06 13.19 14.34 17.10 5.93 16.07
Table entries represent the percentage of patients in each category, by
treatment.
Table 4. Odds Ratios for the Effect of Treatment on Lesion
Volume at 90 Days Corresponding to Various Odds Ratios for
the Effect on mRS at 90 Days
No. Needed to Treat
for an Expected
Total Gain of 1
Point on the mRS
Odds Ratio for the
Effect of
Treatment on
mRS (M)
Odds Ratio for the
Effect of
Treatment on
Lesion Volume
(L)
2 1.5518 2.3099
3 1.3389 1.7070
4 1.2444 1.4827
5 1.1911 1.3662
6 1.1569 1.2949
(null) 1.0000 1.0000
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such calculations made by the authors, those leading to the
numbers needed to treat equal to 2, 3, 4, 5, and 6 have been
selected for display. Also included is the null situation of no
treatment effect. A very rough rule of thumb is that M is the
square root of L.
As odds ratios are larger for lesion volumes, they will be
easier to detect, so that trials powered in terms of lesion
volume will require smaller sample sizes. It is important to
realize the speculative nature of Table 4. If a treatment has a
given effect on lesion volume, and if patients on active
treatment with a given lesion volume behave just like
untreated patients with that same lesion volume, then the
treatment effect on mRS will be as shown. The second
condition is a suitable assumption to make for planning a
large confirmatory phase III trial, and thus Table 4 is
appropriate for use in such planning. Table 4 is not in any
way intended to replace the subsequent phase III trial and has
no basis as proof of any magnitude of treatment effect on
neurologic outcome.
Sample Size Calculations
We start with a conventional power calculation for a phase III
trial based on the mRS outcomes at 90 days, expressed in the
ordered categories shown in Tables 1 and 3 and analyzed
using the Mann-Whitney test applied to data grouped into
categories. (This test is identical to analysis using a propor-
tional odds regression model in the absence of prognostic
factors.) Suppose that placebo patients are expected to follow
the 90-day mRS distribution shown in Table 3. The trial will
be powered to detect a treatment effect with magnitude
expressed as an odds ratio of 1.3389. Thus, if the mRS
distribution on active treatment is also as shown in Table 3,
then there should be a probability of (1) of detecting
significant treatment effect at level  (2-sided). The appro-
priate sample size n is given by10
(1) n 12 (u/2u)
2
(logeM)2 1
j0
6
p j3
Here n is the total sample size, divided equally between 1⁄2n
on active treatment and 1⁄2n on placebo, and u/2 and u are
the upper 1⁄2 and  percentage points of the standard normal
distribution, respectively. The odds ratio M is set to its
clinically relevant value, and p j denotes the proportion of
patients in the jth mRS outcome category, averaging over the
placebo and active treatment arms.
A conventional power calculation for a phase III trial based
on the mRS outcomes at 90 days proceeds as follows. For
M1.3389, and the outcome category probabilities p j taken
from Table 3, equation (1) yields n1518, ie, 759 patients per
treatment arm. This sample size lies at the lower end of the
range of phase III sizes used in practice, as they are usually
powered to detect more modest treatment effects. A similar
calculation can be performed for an analysis based on lesion
volumes. Taking L1.7070 and the probabilities of the 7
outcome categories for lesion volumes from Table 2, equation
(1) yields n468, or 234 patients per treatment arm. This
remains a large sample size for phase II. Although the ideal
policy would be to recruit this number of patients into the
phase II trial, this might be unfeasible in practice. A compro-
mise might be possible. The settings of  and 1 in the
power requirement are suitable for the design of a definitive
phase III study but are perhaps unnecessarily demanding for
phase II. Instead, values such as 0.40 and 10.80
might be considered. The 2-sided significance level of 0.40
corresponds to a 1-sided level of 0.20. A treatment will be
taken forward to phase III if it achieves a 1-sided probability
value 0.20 in favor of smaller lesion volumes relative to
placebo. With this criterion, a totally inactive treatment is
allowed a 20% probability of further study, whereas a
treatment with L1.7070 on the lesion volume outcome,
consistent with an important effect on mRS at 90 days, will
not be taken forward with probability 10.800.20. These
error rates lead to a sample size of n126, or 63 patients per
treatment.
Table 5 reworks these calculations for various target odds
ratios. It can be seen that, for equivalent error rates, the
sample size required to detect a treatment effect on lesion
volume is a little more than a quarter of the eventual sample
size required for phase III, and for the relaxed power
requirement at phase II, a further reduction of almost a
quarter is achieved.
Simulations
Simulations were conducted to evaluate criteria (a), (b), (c),
and (d) for proceeding to phase III, for phase II trials with a
total sample size of 126, or 63 patients per treatment; ie, the
design in the second row of Table 5, corresponding to a
power of 0.8 to detect significance at the level 0.4
(2-sided) when L1.7070. Table 6 presents the proportion
of runs in which the experimental treatment would be
advanced to phase III according to each of the 4 criteria. It
can be seen that both criteria (a) and (b) lead to a type I error
Table 5. Sample Sizes for Phase III and Phase II Trials
Powered to Detect Various Magnitudes of Treatment Effect
NNT M L
nIII nII nII
(0.05, 0.90) (0.05, 0.90) (0.40, 0.80)
2 1.5518 2.3099 670 194 52
3 1.3389 1.7070 1518 468 126
4 1.2444 1.4827 2706 858 232
5 1.1911 1.3662 4230 1364 368
6 1.1569 1.2949 6092 1986 535
NNT indicates number needed to treat.
Table 6. Proportions of Positive Trial Findings for 4 Different
Criteria of Being Positive, Estimated From 100 000-Fold
Simulations
L
Criterion
(a) (b) (c) (d)
1 0.1999 0.2012 0.1664 0.1948
1.7070 0.8006 0.5394 0.7109 0.7352
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rate of 0.2, which is 1⁄2, as theory predicts. For the double
criterion (c), the type I error rate is lower. Raising  to 0.48
in criterion (d) returns the 1-sided type I error rate to just short
of the allowed value of 0.20. Because criterion (d) involves
consideration of both lesion volumes and mRSs, it is more
difficult to meet: the use of a “nominal” value of 0.48
(2-sided) achieves an actual type I error of the magnitude
specified. The power for criterion (a) is 0.80, as intended,
whereas for mRS (criterion b) it is much lower, at 0.54.
Criterion (c), through adding a second requirement to (a),
reduces power to 0.71, and criterion (d) recovers some of the
lost power to reach 0.74.
Discussion
In therapeutic areas such as stroke, definitive evidence on the
efficacy of a novel treatment should be based on clinical
outcomes observed after a lengthy period of follow-up. Phase
II trials to determine whether or not to proceed to such a
phase III study should be smaller and shorter. As a confir-
matory study will follow, a larger type I error is permissible:
mistakes can later be rectified. Relaxation of power is more
troublesome, as discarded treatments cannot easily be re-
stored. One option in phase II is to focus on an intermediate
physiologic end point. If the drug is intended to work by
influencing this end point, then evidence that it does so is
reasonable motivation for taking it further: lack of such
evidence should be sufficient to discard the treatment. Phase
III can be used to determine whether this physiologic effect is
indeed converted into a clinical advantage. In stroke, the
physiologic end point in question might be lesion volume,
and a drug devised to improve clinical outcomes after stroke
by limiting infarct size might be expected to demonstrate a
direct effect on lesion volume before being taken forward.
Expert groups such as STAIR have recommended a search
for suitable surrogate outcomes to be used in phase II.13 Our
approach will be valid only for treatments that directly affect
lesion volume: they would be inappropriate for certain
neuroprotective or restorative strategies. Outcomes relating to
other forms of therapeutic action could be used in place of
lesion volumes in a manner similar to that shown here.
The results presented here were based on lesion volumes at
90 days (or earlier, if it is the last observation carried forward)
because we were comparing volume with functional outcome
at 90 days and because such data were to hand. It could be
advantageous to consider a much earlier imaging end point. If
confounding effects of edema can be discounted, then earlier
assessment may limit losses due to mortality or withdrawal.
Disadvantages of imaging end points must also be consid-
ered: CT is insensitive to small subcortical and posterior
situated infarcts; both CT and MRI may show several lesions,
some of which can be old and thus unrelated to the current
stroke. Careful patient selection can limit these disadvantages.
To calculate the size of such a phase II trial, the worthwhile
reduction in lesion volume (relative to placebo) must be
specified. In this article, we have shown how to specify an
effect that is consistent with a meaningful effect on neuro-
logic outcome. The phase III trial will then determine whether
the potential due to reduction in lesion volumes is indeed
passed on to clinical responses. As the advantage gained
through a direct physiologic effect is likely to be diluted by
other effects before being passed on to the clinical outcome,
the former direct effect is likely to be larger and consequently
easier to detect. In turn, this will justify smaller sample sizes.
In the context of stroke, we have found that further measures,
such as a large relaxation in the limit on type I error and a
smaller reduction in power, are needed to produce phase II
sample sizes that might be contemplated as practical by
investigators. In the calculations, the value of  was set at
0.40. This is a large risk of error but perhaps not as large as
at first apparent. It is a 2-sided risk of error, indicating that if
the treatment were inactive, there would be a probability of
0.20 of proceeding to phase III and a probability of 0.20 of
concluding with equal force that the treatment is doing harm.
The latter conclusion is of limited interest, as the 2 actions
available are to take the treatment forward for further study or
not. Even so, 0.20 is a large risk of taking forward an inactive
treatment. An error is likely to be put right at phase III, so this
is not the public’s risk of receiving an inactive treatment. Of
course, it would be optimal to keep type I error small and
power large. For conventional error rates, the sample size for
an analysis based on lesion volume is given above as n468.
It remains to be seen whether investigators would or should
commit such resources to phase II studies.
The numeric findings of this article are only as good as the
data on which they are based. Trial planners may wish to
rework these calculations with larger databases or databases
more relevant to the patient population that they wish to
study. When devising our own design, we found the VISTA
database to be the most extensive available. It is of interest to
note that the marginal distribution of the mRSs shown at the
foot of Table 1 is similar to that found for placebo patients in
the first SAINT study,2 which reported the following respec-
tive percentages: 11, 20, 12, 13, 21, and 24 (categories 5 and
6 being merged).
Phase II trials often include 2 or 3 dose levels of the
investigational drug in addition to placebo. In that case,
sufficient power is usually required to make each pairwise
comparison with control. In the example of this article, this
would lead to 63 patients per arm and 252 patients altogether
for a 4-arm trial. It will often be better to reduce the number
of dose levels, maybe down to 1, rather than reducing power
below the already low level of 0.80.
The use of the concept of number needed to treat is not
essential to the approach presented. The concept of number
needed to treat has been criticized,14 and taking expectations
over a nominal (rather than interval) scale such as mRS is also
problematic. Nevertheless, as a means of establishing what
magnitude of treatment effect might be of interest, expressing
that effect as an expected reduction in mRS of one third can
be helpful (whether or not one then inverts this value to give
number needed to treat3).
It is of interest to compare the approach presented here
with that of earlier related work.15,16 Those studies estab-
lished that the correlation between MRI measures and neu-
rologic outcomes is statistically significant and determined
sample sizes for a phase II study based on the former end
points. There are 3 principal differences between this earlier
approach and the method presented here: (1) They used
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percentage reperfusion, whereas we used lesion volume; (2)
In considering continuous measures, they calculated sample
sizes using a bootstrapping approach, whereas we used an
explicit formula; and (c) They powered the phase II study for
a treatment difference in terms of imaging outcome that was
selected arbitrarily, whereas we set this difference in terms of
the corresponding effect on the neurologic outcome sought.
The last is the only fundamental difference and constitutes
our main message: here we present a rationale for choosing a
treatment effect in terms of the imaging outcome that relates
to a neurologic effect of a size that is both credible and
clinically important.
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